LRRFIP1P1: A Promising Drug Target / Biomarker (G101290506)

Target Name: LRRFIP1P1

NCBI ID: G101290506

LRRFIP1P1

Other Name(s): LRR binding FLII interacting protein 1 pseudogene 1

LRRFIP1P1: A Promising Drug Target / Biomarker

The gene LRRFIP1P1 is a member of the long non-coding RNA (lnc) family, which plays a crucial role in regulating various cellular processes. LRRFIP1P1 has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

Discovery and Characterization of LRRFIP1P1

The LRRFIP1P1 gene was first identified using transcriptomics experiments using RNA-seq technology. The gene has a length of 2129 nucleotides and an estimated transcriptional level of 18.1% in the brain. LRRFIP1P1 is expressed in various tissues and cells, including brain, heart, and muscle.

The functional characterization of LRRFIP1P1 has been done using a variety of techniques, including RNA-seq, RNA-conversion assays, and in vitro transcription assays. These studies have demonstrated that LRRFIP1P1 is involved in various cellular processes, including cell adhesion, migration, and invasion.

LRRFIP1P1 as a Drug Target

The potential drug target for LRRFIP1P1 is based on its involvement in cell adhesion and migration. LRRFIP1P1 has been shown to play a role in the regulation of tight junction formation and cell-cell adhesion, which are critical for the maintenance of tissue structure and function.

Additionally, LRRFIP1P1 has been shown to be involved in the regulation of cell migration and invasion. Migrating cells require the maintenance of tight junctions, which allow them to move through the body and perform their functions. LRRFIP1P1 has been shown to regulate the formation of tight junctions and the maintenance of cell-cell adhesion during the migration process.

The potential drug target for LRRFIP1P1 is based on its involvement in the regulation of cell adhesion and migration.

LRRFIP1P1 as a Biomarker

LRRFIP1P1 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The expression of LRRFIP1P1 has been shown to be altered in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders.

For example, LRRFIP1P1 has been shown to be downregulated in various cancer types, including breast, ovarian, and prostate cancers. This suggests that LRRFIP1P1 may be a promising target for cancer therapies. Additionally, LRRFIP1P1 has been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. The expression of LRRFIP1P1 has been shown to be altered in individuals with these diseases, suggesting that LRRFIP1P1 may be a promising target for neurodegenerative disease therapies.

Furthermore, LRRFIP1P1 has also been shown to be involved in the regulation of metabolic disorders, including type 2 diabetes. The expression of LRRFIP1P1 has been shown to be altered in individuals with type 2 diabetes, suggesting that LRRFIP1P1 may be a promising target for diabetes therapies.

Conclusion

In conclusion, LRRFIP1P1 is a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. The expression of LRRFIP1P1 has been shown to be altered in various diseases, providing a promising avenue for the development of new therapies. Further research is needed to fully understand the function of LRRFIP1P1 and its potential as a drug target and biomarker.

Protein Name: LRR Binding FLII Interacting Protein 1 Pseudogene 1

The "LRRFIP1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRFIP1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets